Physician profile
Thomas E Dudney
NPI 1235358235
$159,407.03
in general payments reported to CMS, 2019-2025
9 companies · $607 in 2025
The $607 reported for 2025 was more than what 92% of Dentist providers received nationally (typical 2025 total: $70.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $16K · 2021: $18K · 2022: $26K · 2023: $8,081 · 2024: $19K · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $22K · Consulting Fee: $2,750 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,000 · Food and Beverage: $888 · Travel and Lodging: $546 · Gift: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $21,500.00 |
| Consulting Fee | $2,750.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,000.00 |
| Food and Beverage | $888.11 |
| Travel and Lodging | $546.22 |
| Gift | $436.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gc America INC. | $68,570.90 | 2019-2025 | Mi Paste, G-Aenial, Equia |
| Bisco, INC. | $46,599.28 | 2019-2024 | |
| Shofu Dental Corp | $21,000.00 | 2019-2024 | |
| Pulpdent Corporation | $14,750.00 | 2019-2024 | |
| Ivoclar Vivadent, INC. | $3,835.75 | 2019 | |
| Doxa Dental, INC. | $2,500.00 | 2019-2021 | |
| Ultradent Products INC | $1,133.45 | 2019-2025 | Opalescence |
| Zest Holdings, LLC | $1,000.00 | 2019 | |
| Dmg America LLC | $17.65 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dudney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.